Clinical Trial Update: Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ofatumumab maintenance vs no further treatment in relapsed chronic lymphocytic leukemia after induction therapy; trial terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ofatumumab (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Leukaemia, Lymphocytic, Chronic | Phase 3 | Status: TERMINATED | Results posted: 2015-04-21